SENS.L Regulatory News (SENS)

COVID risk prediction algorithm achieves UK regulatory approval

First of a number of clinical AI algorithms being developed on the Company's SENSE

 clinical and operational algorithm engine

SYNE-COV product was developed in collaboration with Chelsea & Westminster Hospitals

NHS Foundation Trust and will now be offered to NHS Trusts across the UK.

Oxford, U.K. 01 March 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the UK Clinical AI company, today announces that its SYNE-COVTM machine learning algorithm for COVID risk prediction has achieved regulatory approval for use in the UK.

About SYNE-COV

SYNE-COV analyses over 60 variables in the patient electronic health record to generate a prediction of the likelihood of a COVID positive patient developing severe disease, requiring ventilation or admission to intensive care. It provides the risk prediction, together with an explanation of the result, to help clinicians manage patients admitted to hospital with COVID infection.

The SYNE-COV product was developed in collaboration between Sensyne and the Chelsea & Westminster Hospitals NHS Foundation Trust This is the first algorithm developed from the SENSETM clinical and operational algorithm engine to achieve UK regulatory approval. SENSE generates Clinical AI algorithms (called SYNEs) from the analysis of data in patient electronic health records to provide decision support to clinicians. The Company has several algorithms currently in development across multiple medical conditions, which subject to regulatory approval, it intends to market to healthcare providers in the UK and internationally.

Following regulatory approval, Sensyne is now able to market SYNE-COV across the UK. Sensyne will market the algorithm to NHS Trusts in order to help them with COVID preparedness and to deploy the algorithm in good time for the 2021/22 winter season.

Dominic Conlin, Hospital Director, Chelsea and Westminster Hospital NHS Foundation Trust, said:

 "We're excited by the possibilities this offers.  This is individualised care by using patients' own data to stratify risks and predict responses to clinical treatments, informing and supporting clinical decision making. This is a real step in taking forward digital innovation, data integration and analytics to enhance patient care in the NHS."

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

"This is the first Sensyne Clinical AI algorithm to achieve regulatory approval that has been developed using our SENSE clinical AI platform. The SENSE engine is expected to be able to generate clinical algorithms across a range of medical conditions that will provide real-time clinical decision making support. Achieving the first regulatory approval is an important milestone for the Company and we look forward to being able to roll SYNE-COV out to the NHS."

-ENDS-

For more information please contact:

About Sensyne Health www.sensynehealth.com

Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

About SYNE-COV

SYNE-COV provides clinicians with near real-time risk prediction scores for three outcomes associated with COVID-19 infection; risk of intensive care unit (ICU) admission, the need for invasive mechanical ventilation and in-hospital mortality. The algorithm uses over 60 variables within an individual patient's health records and analyses them in near real-time against the hospital's comprehensive database of electronic health records. This informs clinicians making clinical decisions on how to treat each patient, taking into account their particular circumstances.

Sensyne worked with critical care clinicians at Chelsea & Westminster Hospital to develop and test the algorithm, demonstrating that the use of SYNE-COV was able to predict future clinical events from early patient data, accurately predicting the need for mechanical ventilation and ICU admission and in-hospital mortality. The financial return generated from the commercialisation of this algorithm will be shared with Chelsea & Westminster Hospital. The Chelsea & Westminster Hospital is also a shareholder in Sensyne.